VIVUS Board Names Michael Astrue as Chairman, Tony Zook as CEO

VIVUS, Inc.

("VIVUS"), which recently began selling the obesity drug Qsymia® (phentermine and topiramate extended-release) capsules CIV in the United States, today announced that its Board of Directors has appointed Michael Astrue to serve as its Chairman and Anthony Zook to serve as its Chief Executive Officer, effective today. Mr. Astrue formerly served as Chief Executive Officer of Transkaryotic Therapies, Chairman of the Massachusetts Biotechnology Council, and Commissioner of Social Security. Mr. Zook formerly served as Executive Vice President, Global Commercial Operations for AstraZeneca and President of Medimmune.